Sophiris Bio, Inc.
OTC: SPHS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 6
- Headquarters
- La Jolla, United States
- IPO year
- 2008
- Website
- https://www.sophirisbio.com
Loading SPHS…
Loading profile data…Frequently asked questions about SPHS
What does Sophiris Bio, Inc. (SPHS) do?
Sophiris Bio, Inc. is a biopharmaceutical entity currently in the clinical trial phase, dedicated to pioneering treatments for conditions affecting the urinary system. Its flagship investigational compound, PRX302 (topsalysin), is presently undergoing Phase III trials. This candidate is being evaluated for its efficacy in alleviating lower urina...
Where does SPHS trade?
Sophiris Bio, Inc. (SPHS) trades on the Other OTC.
What sector is SPHS in?
Sophiris Bio, Inc. (SPHS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Where is Sophiris Bio, Inc. headquartered?
Sophiris Bio, Inc. is headquartered in United States.
Does SPHS pay a dividend?
Sophiris Bio, Inc. (SPHS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SPHS go public?
Sophiris Bio, Inc. (SPHS) completed its initial public offering in 2008.